Summary of Liquidia Corp (LQDA) 2025 Conference Call Company Overview - **Company**: Liquidia Corp (LQDA) - **Product**: Eutrebia, an inhaled treprostinil formulation approved for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD) [4][12] Key Points and Arguments Product Approval and Launch - Eutrebia received approval on May 23, 2025, for both PAH and PHILD, allowing simultaneous launch into both indications [4][12] - The product is based on PRINT technology, enabling the creation of dry particles in the respirable range, which enhances efficacy, safety, and convenience [4][5] Differentiation Factors - **Safety**: Eutrebia avoids upper airway deposition, reducing cough and throat irritation, which are common with incumbent products [5] - **Efficacy**: The formulation allows for higher therapeutic doses, potentially 3 to 4 times the current standard [5] - **Convenience**: The low resistance device does not require energy for de-aggregation, making it easier for patients to use [5][6] Market Potential - Historical precedents in the PAH market suggest that addressing safety, efficacy, and convenience can lead to significant market share conversion within 12 to 18 months [6][10] - The oral prostacyclin market is valued at $2 billion in North America, with Tyvaso generating similar revenue, indicating a substantial opportunity for Eutrebia [32] Pricing and Patient Access - Eutrebia is priced at parity with Tyvaso DPI, ensuring competitive positioning [12][13] - A 28-day voucher program allows patients to start therapy immediately while awaiting reimbursement, enhancing access [13][14] Launch Metrics and Supply Chain - Shipments began five business days post-approval, with patient prescriptions filled shortly thereafter [15] - The company has built a robust supply chain, ensuring sufficient inhaler availability for a successful launch [16][17] Sales Strategy - Liquidia has a sales force of approximately 60, targeting 6,500 key prescribers across 150 centers of excellence and 750 community centers [21][22] - The company aims to match or exceed the share of voice of competitors, focusing primarily on Eutrebia [23] Clinical Data and Reception - Initial data from the ASCENT study shows promising tolerability and efficacy, with only one dropout due to a respiratory infection among the first 20 patients [25][26] - There is significant enthusiasm among doctors for transitioning patients from nebulized Tyvaso to Eutrebia, indicating a potential shift in treatment paradigms [29] Future Studies and Development - A prospective study will be initiated to demonstrate the efficacy of transitioning patients from nebulized therapies to Eutrebia [31] - Liquidia is also developing L606, a next-generation liposomal formulation aimed at providing a twice-daily dosing option [46][49] Legal Landscape - Liquidia has faced multiple lawsuits from United Therapeutics but has been successful in defending its position, with ongoing litigation expected to resolve favorably [59][60] Financial Outlook - The company anticipates reaching profitability within three to four quarters post-launch, supported by efficient processes and existing cash reserves [37][38] Additional Important Points - Liquidia is focused on changing the standard of care for PAH and PHILD patients, aiming to establish Eutrebia as the first-choice treatment option [32][36] - The company is preparing to provide detailed launch metrics and patient access information in future earnings calls [18][19] This summary encapsulates the critical insights from the Liquidia Corp conference call, highlighting the company's strategic positioning, product differentiation, market potential, and future growth plans.

Core Viewpoint - United Therapeutics has seen a 9% increase in share price over the past month, outperforming the S&P 500, but estimates have trended downward recently, raising questions about future performance leading up to the next earnings report [1][2]. Group 1: Earnings Performance - The last earnings report for United Therapeutics was about a month ago, and the stock has performed positively since then [1]. - The stock has a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [4]. Group 2: Estimates and Scores - Estimates for United Therapeutics have been revised downward over the past month, suggesting a cautious outlook [2][4]. - The company has a Growth Score of B, a Momentum Score of F, and a Value Score of B, resulting in an aggregate VGM Score of B, placing it in the second quintile for investment strategy [3].

Summary of Liquidia's Conference Call Company Overview - **Company**: Liquidia - **Industry**: Biotech, specifically in the cardiopulmonary space - **Lead Product**: Eutrebia, a treatment for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PHILD) [3][12] Key Points and Arguments Product Development and Approval - Liquidia is approaching its PDUFA date for Eutrebia, which is set for May 24, indicating a potential approval for the treatment of PAH and PHILD [3][15] - Eutrebia utilizes proprietary print technology to create a dry powdered formulation of treprostinil, allowing for better lung deposition and tolerability [3][5] - The company has developed five launch strategies, including product profile development, a best-in-class sales force, patient support services, product availability, and payer access [4][5] Market Dynamics - The reference brand, United Therapeutics' Tyvaso, has a sales run rate of approximately $2 billion, with a market characterized by less than 20% penetration in PHILD [19][21] - Liquidia estimates the PHILD market to have around 60,000 patients, presenting significant growth opportunities [21][30] - The PAH market is described as crowded, with Liquidia aiming to position Eutrebia as the first choice among prostacyclins due to its ability to titrate to higher doses [22][23] Competitive Landscape - Liquidia is aware of ongoing litigation from United Therapeutics, which has filed multiple patents against them to delay Eutrebia's market entry [8][11] - The company is confident in its legal position and is committed to providing alternative treatments for patients [12][69] Sales and Marketing Strategy - Liquidia has a 50-person sales force with extensive experience in PAH, focusing on building relationships with healthcare providers [36][38] - The sales force has engaged in unbranded promotional efforts to educate physicians about the product and its technology [38][39] - The company plans to ensure broad access to Eutrebia through relationships with payers, targeting a market mix of approximately 50% Medicare Part D and 35-40% commercial [48][49] Product Differentiation - Eutrebia is designed to be easy to use, requiring no refrigeration and allowing for quick inhalation [51][55] - The device is familiar to pulmonologists, which may facilitate adoption among patients [55][56] - Liquidia emphasizes the importance of patient-reported outcomes and quality of life improvements as key measures of success [58][61] Future Outlook - Liquidia is preparing for a Phase 3 study of L606, a liposomal sustained release formulation, which could provide a once-daily treatment option [64][66] - The company is focused on maximizing the benefits of inhaled treprostinil and is optimistic about its long-term positioning in the market [66] Additional Important Information - Liquidia has been proactive in manufacturing commercial supply in anticipation of approval, ensuring sufficient product availability at launch [44][45] - The company is committed to addressing the needs of patients with PAH and PHILD, aiming to provide effective treatment options [12][69]

Financial Data and Key Metrics Changes - The company reported overall revenue growth of 18% in Q1 2025, driven by Tyvaso DPI revenues [18][19] - Non-GAAP net income for Q1 2025 was $22 million, representing a 43% increase compared to the same period in 2024 [21] - Net income for Q1 2025 was $13 million, a 24% increase from $11 million in Q1 2024 [20] Business Line Data and Key Metrics Changes - The endocrine business experienced a 20% growth in new prescriptions (NRxs) and a 14% growth in total prescriptions (TRxs) [4] - Tyvaso collaboration generated $30 million in royalty revenue and $29 million in manufacturing revenue for Q1 2025 [5][19] - Afrezza net revenues increased by 3% to $15 million, although impacted by one-time adjustments and shipment timing [19] Market Data and Key Metrics Changes - The orphan lung opportunity, particularly with Tyvaso DPI, is expected to exceed $1 billion by the end of the decade, with a focus on the US and Japan [10] - The company anticipates significant revenue potential from pediatric patients, estimating that a 10% market share could yield $150 million in net revenue [24] Company Strategy and Development Direction - The company is focusing on expanding its pediatric market strategy for Afrezza, which will differ significantly from the adult market approach [66] - The strategy includes leveraging strong data from recent studies and enhancing the sales force's presence [63][64] - The company aims to build shareholder value through various catalysts, including the anticipated approval of pediatric indications and ongoing clinical trials [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Afrezza, particularly with new data and improved sales execution [63] - The company is optimistic about the upcoming pediatric indication approval and its potential impact on market uptake [66] - Management acknowledged the challenges posed by the macroeconomic environment but believes the company can navigate these headwinds effectively [87] Other Important Information - The company has activated 85% of sites for the MannKind 101 study across four countries, with 55 patients randomized and minimal dropouts [12][13] - The company is preparing for several upcoming scientific conferences to present new data and engage with the medical community [26] Q&A Session Summary Question: Can you provide initial thoughts on the Phase two-three trial design for MANKIND-201? - The company is considering a several dose arm trial compared to placebo, with ongoing discussions regarding patient selection [30][31] Question: Are you looking to measure FVC in the IPF study? - The company plans to look at multiple doses and aims to see a delta from placebo, focusing on patient enrollment for future phases [34][36] Question: What is the rationale behind the label update for adults? - The company is seeking to improve dosing conversion for better control and anticipates scaling faster in the adult market [45][46] Question: How are you thinking about the potential impact to supply chain for Afrezza? - The company does not anticipate significant supply chain impacts due to its US manufacturing base and is managing potential tariff issues [47][48] Question: Can you provide insights on the treatment landscape for NTM and the role of 201? - The company believes inhaled natendib could serve as a background therapy for new drugs, focusing on expanding treatment options for patients [52][54]

Financial Data and Key Metrics Changes - The company reported a 18% increase in overall revenues for Q1 2025, driven by strong performance in Tyvaso DPI royalties and collaboration services [17][18] - Non-GAAP net income for Q1 2025 was $22 million, representing a 43% increase compared to the same period in 2024 [20] - The company ended the quarter with cash and investments totaling $198 million, allowing for continued investment in its pipeline [20] Business Line Data and Key Metrics Changes - The endocrine business experienced a 20% growth in new prescriptions (NRxs) and a 14% growth in total prescriptions (TRxs) [4] - Tyvaso collaboration generated $30 million in royalty revenue and $29 million in manufacturing revenue for Q1 2025, marking a 32% and 18% increase respectively compared to the prior year [5][18] - Afrezza net revenues were $15 million, a 3% increase year-over-year, although impacted by one-time adjustments and shipment timing [18][19] Market Data and Key Metrics Changes - The orphan lung opportunity, particularly with Tyvaso DPI, is expected to exceed $1 billion by the end of the decade, with a focus on the US and Japan [10] - The company anticipates significant market potential in the pediatric segment, estimating that a 10% market share could yield approximately $150 million in net revenue [22] Company Strategy and Development Direction - The company is focusing on expanding its pediatric offerings and anticipates filing for pediatric expansion in mid-2025 [4][22] - The strategy includes leveraging strong data from recent studies to enhance market penetration and address the pediatric diabetes market differently than the adult market [65][66] - The company aims to build shareholder value through a series of anticipated catalysts, including the approval of pediatric indications and ongoing clinical trials [21][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Afrezza, particularly with the positive reception of recent data and the potential for pediatric approval [6][61] - The company is optimistic about navigating economic headwinds, including tariffs, due to its predominantly US-based manufacturing [46][85] - Management highlighted the importance of ongoing clinical trials and the potential for new product launches to drive future growth [52][81] Other Important Information - The company is actively preparing for several upcoming scientific conferences to present new data and engage with the investment community [25] - Management noted that the current supply chain situation is manageable, with key products either exempt from tariffs or positioned to navigate potential impacts [46][47] Q&A Session Summary Question: Can you provide initial thoughts on the Phase two-three trial design for MANKIND-201? - Management indicated that they are still finalizing the trial design and have not provided extensive guidance on FDA feedback yet [29][30] Question: Are you looking to measure FVC in the IPF study? - Management confirmed that they will be looking at multiple doses and measuring delta from placebo, but specifics are still being finalized [34][35] Question: What is the rationale behind the label update for adults? - Management explained that the label change aims to improve dosing and control, with expectations for approval in Q4 [44] Question: How do you see the treatment landscape evolving for NTM and IPF? - Management noted the challenges in treating these diseases and emphasized the potential for their products to provide better tolerability and efficacy [52] Question: What are your thoughts on adherence in pediatric diabetes? - Management expressed optimism about adherence in pediatric patients, noting that caregivers are typically more diligent and that the product's profile may appeal to parents [72][74]

Financial Data and Key Metrics Changes - The company reported overall revenue growth of 18% in Q1 2025, driven primarily by Tyvaso DPI revenues [17][18] - Non-GAAP net income for Q1 2025 was $22 million, representing a 43% increase compared to the same period in 2024 [20] - Net income for Q1 2025 was $13 million, a 24% increase from $11 million in Q1 2024 [19] Business Line Data and Key Metrics Changes - The endocrine business experienced a 20% growth in new prescriptions (NRxs) and a 14% growth in total prescriptions (TRxs) [4] - Tyvaso collaboration generated $30 million in royalty revenue and $29 million in manufacturing revenue for Q1 2025 [5][18] - Afrezza net revenues increased by 3% year-over-year to $15 million, although impacted by one-time adjustments and shipment timing [18] Market Data and Key Metrics Changes - The orphan lung opportunity market is projected to exceed $1 billion by the end of the decade, with a focus on the US and Japan [9] - The company anticipates significant revenue potential from pediatric patients, estimating that a 10% market share could yield $150 million in net revenue [22] Company Strategy and Development Direction - The company is focusing on expanding its pediatric market strategy for Afrezza, which will differ significantly from the adult market approach [65] - The strategy includes leveraging positive clinical data and enhancing educational outreach to healthcare providers [62][64] - The company aims to maintain a strong financial position with minimal debt while pursuing growth opportunities in its pipeline [3] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Afrezza, particularly with the anticipated pediatric indication approval [17][21] - The company is optimistic about the upcoming catalysts, including the completion of key trials and potential new product launches [21][24] - Management acknowledged the challenges posed by the macroeconomic environment but believes the company is well-positioned to navigate these headwinds [86] Other Important Information - The company has activated 85% of its sites for the MannKind 101 study across four countries, with 55 patients randomized and minimal dropouts [12] - The company is preparing for several upcoming scientific conferences to present new data and engage with the medical community [24] Q&A Session Summary Question: Can you provide initial thoughts on the Phase 2/3 trial design for MannKind 201? - Management indicated that discussions with the FDA are ongoing and that the trial design will likely involve several dose arms compared to placebo [28][30] Question: Are you looking to measure FVC in the IPF study? - Management confirmed that they are considering multiple doses and will analyze the data for a delta from placebo [34][35] Question: What is the rationale behind the label update for adults? - Management explained that the update aims to improve dosing efficiency and enhance adult uptake, with a focus on scaling faster [44][45] Question: How do you see the treatment landscape evolving for IPF? - Management noted the challenges in treating IPF and emphasized the potential for their inhaled therapies to provide better tolerability and efficacy [52][54] Question: How is the company managing supply chain impacts? - Management stated that the majority of manufacturing is US-based, minimizing tariff impacts, and they are confident in managing supply chain challenges [46][48]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $3.1 million, an increase from $3.0 million in Q1 2024, primarily due to the promotion agreement despite lower sales volumes [12] - Research and development expenses decreased by 31% to $7.0 million from $10.1 million year-over-year, mainly due to a reduction in personnel expenses as the focus shifted towards commercialization preparations [13] - General and administrative expenses increased by 48% to $30.1 million from $20.2 million, driven by higher personnel costs and legal fees related to ongoing litigation [14] - The net loss for Q1 2025 was $38.4 million, or $0.45 per share, compared to a net loss of $30.1 million, or $0.40 per share, in Q1 2024 [14] Business Line Data and Key Metrics Changes - The company is preparing for the potential launch of Eutrebia, an inhaled dry powder formulation for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD) [6][7] - Cohort A of the ASCENT study is fully enrolled with over 50 patients, showing positive trends in dosing and tolerability [8] Market Data and Key Metrics Changes - The company anticipates a significant market opportunity in the inhaled treprostinil market, estimated at $2 billion, with additional opportunities in the oral prostacyclines market [65] - The expected payer mix for the prostacyclin market includes approximately 50% Medicare, 35% commercial, 10% Medicaid, and 5% other [71] Company Strategy and Development Direction - The company is focused on five strategic areas for the launch of Eutrebia: developing a best-in-class product profile, ensuring robust product availability, preparing a full suite of patient support services, establishing strong payer access, and maintaining a competitive share of voice in the market [7][10][11] - The company aims to transition patients from existing therapies to Eutrebia, emphasizing its differentiated product profile and ease of use [9][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming launch of Eutrebia, highlighting the favorable court ruling against United Therapeutics as a positive development [6][7] - The management team is optimistic about the potential for Eutrebia to become the first-choice treatment for patients with PAH and PHILD [16] Other Important Information - The company is preparing for data presentations at the American Thoracic Society's International Conference, showcasing interim results from the ASCENT study [8][51] - The company is also working on a global study for L606, a liposomal sustained release formulation of treprostinil, expected to initiate by the end of the year [29] Q&A Session Summary Question: Does United Therapeutics have any injunctive value left on the dismissed cross claim? - Management clarified that there are currently no active proceedings from United Therapeutics seeking to block FDA approval for Eutrebia, and the dismissal was without prejudice, meaning they could attempt to refile [20][22] Question: What are the patient baseline characteristics for the upcoming transition studies? - The transition study will focus on patients with PHILD currently on Tyvaso, evaluating safety and efficacy during the transition to Eutrebia [26][27] Question: What is the level of awareness of Eutrebia among targeted physicians? - Awareness is expected to increase significantly post-launch, with a comprehensive marketing strategy in place to ensure that healthcare providers are informed about Eutrebia's benefits [60][61] Question: What is the anticipated payer mix for PAH and PILD? - The expected payer mix includes approximately 50% Medicare, 35% commercial, 10% Medicaid, and 5% other [71] Question: Can you provide details on the four ninety-four patent infringement suit? - Management refrained from commenting on the specifics of the lawsuit, stating it is in the early stages [72]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $3.1 million, a slight increase from $3.0 million in Q1 2024, primarily due to the promotion agreement despite lower sales volumes [11] - Research and development expenses decreased by 31% to $7.0 million from $10.1 million year-over-year, attributed to a shift in focus towards commercialization preparations for Eutrebia [12] - General and administrative expenses increased by 48% to $30.1 million from $20.2 million, driven by higher personnel costs and legal fees related to ongoing litigation [13] - The net loss for Q1 2025 was $38.4 million, or $0.45 per share, compared to a net loss of $30.1 million, or $0.40 per share, in Q1 2024 [13] Business Line Data and Key Metrics Changes - The company is focusing on the potential launch of Eutrebia, an inhaled dry powder formulation for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD) [5][6] - Cohort A of the ASCENT study is fully enrolled with over 50 patients, showing positive trends in dosing and tolerability compared to previous studies [7] Market Data and Key Metrics Changes - The company anticipates a significant market opportunity in the inhaled treprostinil market, estimated at $2 billion, with additional opportunities in the oral prostacyclines market [66] - The expected payer mix for the prostacyclin market includes approximately 50% Medicare, 35% commercial, 10% Medicaid, and 5% other [73] Company Strategy and Development Direction - The company is preparing for the launch of Eutrebia by focusing on five strategic areas: product profile development, sales force readiness, patient support services, product availability, and payer access [6][10] - The company aims to position Eutrebia as a best-in-class therapeutic alternative for patients with PAH and PHILD [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming launch of Eutrebia, highlighting the favorable court ruling against United Therapeutics as a positive development [5][6] - The management team is optimistic about the differentiated product profile of Eutrebia and its potential to capture market share from existing therapies [10][66] Other Important Information - The ASCENT study data will be presented at the American Thoracic Society's International Conference, showcasing the product's tolerability and efficacy [7][56] - The company is actively preparing for potential legal challenges from competitors but remains confident in its position [22] Q&A Session Summary Question: Does United Therapeutics have any injunctive value left on the dismissed cross claim? - Management clarified that there are currently no active proceedings from United Therapeutics seeking to block Eutrebia's approval, and the dismissal was without prejudice, allowing for potential future actions [20][22] Question: What are the patient baseline characteristics for the upcoming transition studies? - The transition study will focus on patients with PHILD currently on Tyvaso, evaluating safety and efficacy during the transition to Eutrebia [26][27] Question: What is the company's strategy for converting patients to the dry powder formulation? - Management believes Eutrebia's formulation will provide a better patient experience, and they plan to target new patient starts initially before transitioning existing nebulized patients [33][36] Question: What will the prescriber support team look like? - The prescriber support team will leverage extensive experience in the field to enhance the prescribing experience and ensure patient access to Eutrebia [44][46] Question: What is the expected payer mix for PAH and PILD? - The anticipated payer mix includes about 50% Medicare, 35% commercial, and 10% Medicaid [73] Question: Can you provide details on the four ninety-four patent infringement suit? - Management refrained from commenting on the specifics of the lawsuit, stating it is in the early stages [75]

Company Overview - Liquidia Technologies, Inc. (LQDA) shares increased by 13.2% to close at $15.83, with notable trading volume compared to typical sessions, following a 1.1% loss over the past four weeks [1][2] Recent Developments - The U.S. District Court for the District of Columbia dismissed a cross-claim by United Therapeutics challenging Liquidia's amendment to its new drug application for Yutrepia, which now includes treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2] Financial Expectations - Liquidia is expected to report a quarterly loss of $0.42 per share, reflecting a year-over-year increase of 22.2%, with revenues projected at $3.31 million, up 11.4% from the previous year [3] - The consensus EPS estimate for Liquidia has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Liquidia Technologies operates within the Zacks Medical - Biomedical and Genetics industry, where CRISPR Therapeutics AG (CRSP) also competes, having closed 1.4% higher at $38.25 and showing a 15.5% return over the past month [4]

Core Insights - United Therapeutics reported $794.4 million in revenue for Q1 2025, a 17.2% increase year-over-year, with an EPS of $6.63 compared to $6.17 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $726.19 million by 9.39%, and the EPS also surpassed the consensus estimate of $6.29 by 5.41% [1] Revenue Breakdown - U.S. Revenues: $749.60 million, exceeding the average estimate of $695.02 million, representing a 16.9% year-over-year increase [4] - Rest-of-World Revenues: $44.80 million, surpassing the average estimate of $27.05 million, reflecting a 23.8% year-over-year increase [4] - Tyvaso Revenue in the U.S.: $441.10 million, compared to the average estimate of $405.30 million [4] - Remodulin Revenue in the U.S.: $120.20 million, exceeding the average estimate of $113.15 million [4] - Adcirca Revenue: $6 million, below the average estimate of $4.77 million, showing a 6.3% decrease year-over-year [4] - Orenitram Revenue: $120.70 million, surpassing the average estimate of $111.47 million, with a 13.7% year-over-year increase [4] - Tyvaso Revenue: $466.30 million, exceeding the average estimate of $413.63 million, with a remarkable 105% year-over-year increase [4] - Remodulin Revenue: $138.20 million, above the average estimate of $126.42 million, reflecting an 8% year-over-year increase [4] - Unituxin Revenue: $58.20 million, below the average estimate of $62.95 million, showing a 0.3% decrease year-over-year [4] - Tyvaso DPI Revenue: $302.50 million, exceeding the average estimate of $271.57 million [4] - Nebulized Tyvaso Revenue: $163.80 million, surpassing the average estimate of $137.44 million [4] - Other Products Revenue: $5 million, below the average estimate of $5.68 million, reflecting a 19.4% decrease year-over-year [4] Stock Performance - Shares of United Therapeutics have returned -2% over the past month, compared to the Zacks S&P 500 composite's -0.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]